Weld Capital Management’s Theravance Biopharma TBPH Stock Holding History

Weld Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-13,117	Closed	-$340K	–	700
2019 Q4	$340K	Buy	+13,117	New	+$255K	0.07%	441

Other funds holding TBPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFS

Link Fund Solutions London, United Kingdom $157M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Weld Capital Management's TBPH Position: Q1 2020 in Review

Weld Capital Management sold out of Theravance Biopharma (TBPH) in Q1 2020, closing a stake of 13,117 shares — an estimated $340K sold.

Weld Capital Management first reported a position in TBPH in Q4 2019 and held it in 1 quarter. The position peaked at $340K in Q4 2019. 105 funds tracked by Wall St. Rank hold TBPH as of Q1 2020.

Weld Capital Management reported no remaining Theravance Biopharma position as of Q1 2020 after selling out during the quarter.
Weld Capital Management sold 13,117 Theravance Biopharma shares in Q1 2020, an estimated $340K.
Weld Capital Management first reported a position in Theravance Biopharma in Q4 2019 and held it in 1 quarter.
Weld Capital Management's Theravance Biopharma position peaked at $340K in Q4 2019.
105 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2020.

Based on Weld Capital Management's 13F filing for Q1 2020, filed 15 May 2020.